ALKS 3831 is composed of samidorphan, a mu-opioid receptor antagonist, which is co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.
This study investigates whether contralateral delay activity occurs early in schizophrenia, possibly indicating that visual short-term memory deficits are a core feature of the disorder.
This study highlights the importance of transdiagnostic approaches to psychiatry.
Untreated stress amongst healthcare professionals can lead to a multitude of issues while prolonged stress can contribute to burnout. In order to ensure the safety of both clinicians and patients, effective and feasible interventions are needed for individuals and organizations.
A recent study aimed to assess the ability of classifiers to identify individuals with schizophrenia, autism spectrum disorder, and typical development based on findings from magnetic resonance imaging.
In a phase 3, double-blind trial, the effect of combined olanzapine and samidorphan treatment compared with treatment with olanzapine alone on the weight profile of patients with schizophrenia was evaluated.
Authors of a paper share their perspectives on the topic of chronic pain in individuals with mental health disorders.
Compared with usual treatment, the use of long-acting injectable antipsychotics significantly increased the time to first hospitalization in patients with early-phase schizophrenia.
Polygenic risk scores predict the progression from unipolar depression to bipolar or psychiatric disorders.
Dexmedetomidine is currently available as a solution for intravenous infusion for use in clinical anesthesia and sedation in an intensive care setting.
